Livzon’s Lecankitug Accepted by NMPA as First Domestic Dual IL‑17A/F Psoriasis Drug
Livzon Pharmaceutical Group Inc. (HKG: 1513) announced that China’s National Medical Products Administration (NMPA) accepted...
Company
Novo Nordisk’s Sogroya Wins NMPA Approval for Pediatric Growth Hormone Deficiency
Novo Nordisk (NYSE: NVO) announced that its once‑weekly long‑acting growth hormone (LAGH) injection, Sogroya (somapacitan), received...
J&J’s Amivantamab Subcutaneous Wins China Approval for NSCLC
Johnson & Johnson (J&J, NYSE: JNJ) announced that its Amivantamab Injection (Subcutaneous), marketed as RYBREVANT, received...
Hybio Pharmaceutical, Dr. Reddy’s Forge Peptide API Partnership
Hybio Pharmaceutical and Dr. Reddy’s Laboratories entered a strategic partnership, signing a non‑binding Term Sheet...
NDRC Expands Foreign Investment in Healthcare with 2025 Catalogue
The National Development and Reform Commission (NDRC) issued the “Catalogue of Industries Encouraging Foreign Investment...
Shionogi Acquires RADICAVA ALS Business for $2.5 Billion from Tanabe Pharma
Shionogi & Co., Ltd. (Japan) announced it will acquire 100% of the shares of a...
Novo Nordisk’s Wegovy Wins China Cardiovascular Approval in Weight-Loss Market Expansion
Novo Nordisk (NYSE: NVO) announced that China’s National Medical Products Administration (NMPA) approved Wegovy (semaglutide)...
Aosaikang’s Delafloxacin Wins NMPA Approval as First Fluoroquinolone for China Infections
Beijing Aosaikang Pharmaceutical Co., Ltd. (SHE: 002755) announced that China’s National Medical Products Administration (NMPA)...
Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal
Coherent Biopharma announced an exclusive licensing agreement with MultiValent Biotherapies, Inc. for CBP‑1018, a bispecific...
3SBio’s rhTPO Wins NMPA Approval for Liver Disease Thrombocytopenia Before Surgery
3SBio Inc. (HKG: 1530) announced that its Recombinant Human Thrombopoietin (rhTPO) injection received National Medical...
Gilead’s Seladelpar Wins China Hainan Approval for PBC Treatment
Gilead Sciences (NASDAQ: GILD) announced that Seladelpar (marketed as Livdelzi), a potent and selective PPARδ...
Alphamab JSKN003 ADC FDA Breakthrough Therapy Targets Ovarian Cancer
Alphamab Oncology (HKG: 9966) announced that its independently developed HER2‑targeting biparatopic antibody‑drug conjugate (ADC), JSKN003,...
Jemincare JMX-2005 PAD Injection Secures NMPA Clinical Trial Approval
Jiangxi Jemincare Group (SHA: 603222) announced that its Class 2.2 and Class 2.4 new drug application for...
J&J TREMFYA Pediatric Psoriasis EC Approval Targets First IL-23 Indication
Johnson & Johnson (J&J, NYSE: JNJ) announced that the European Commission (EC) has extended the...
Takeda Zasocitinib TYK2 Phase III Shows Positive Psoriasis Results
Takeda Pharmaceutical Company (TYO: 4502, NYSE: TAK) announced positive topline results from two pivotal Phase III...
Lilly Imlunestrant Breast-Cancer EMBER-3 Shows 38% Risk Reduction
Eli Lilly (NYSE: LLY) announced updated results from the Phase III EMBER‑3 clinical trial evaluating its...
IVIEW GVB-2001 Gene Therapy Treats First POAG Patient Successfully
IVIEW Therapeutics Inc. announced the successful treatment of the first patient with primary open-angle glaucoma...
Novartis MSD Sanofi TrumpRx Deal Targets Medicaid Pricing
Novartis (NYSE: NVS), MSD (NYSE: MRK), and Sanofi (NASDAQ: SNY) announced partnerships with the U.S....
Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial
Novabio Therapeutics, a China‑based clinical‑stage biotech, announced the successful completion of first patient dosing in...
Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis
Grand Pharmaceutical Group Limited (HKG: 0512) announced that its China‑based Phase III clinical trial for TLX591‑CDx...